REFERENCES
- Tinat J, Caron O, Bressac-de Paillerets B, 2009 Version of the chompret criteria for li fraumeni syndrome. J Clin Oncol. 2009;27:e108–e109.
- Zils K, Bielack S. Therapeutic management of osteosarcoma. Hospital Pharmacy Europe. 2011;56:51–56.
- Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. In: Pagon RA, Adam MP, Bird TD, , eds. GeneReviewsTM [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2013. http://www.ncbi.nlm.nih.gov/books/NBK1311/Published January 19, 1999. Updated April 11, 2013.
- Villani A, Tabori U, Schiffman J, Biochemical and imaging surveillance in germline TP53 mutation carries with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12:559–567.
- Jaffe N, Pearson P, Yasko AW, Single and multiple metachronous osteosarcoma tumors after therapy. Cancer. 2003;98:2457–2466.
- Mirra JM. Multifocal osteosarcoma. In: Mirra JM, ed. Bone Tumors. 1st ed. Beckenham and Philadelphia, PA: Lea & Febiger; 1989;1:344–347.
- Aung L, Gorlick R, Healey JH, Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol. 2003;21: 342–348.
- Franke M, Hardes J, Helmke K, Solitary skeletal osteosarcoma recurrence. findings from the cooperative osteosarcoma study group. Pediatr Blood Cancer. 2011;56:771–776.